MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2022007949

Медицинская библиотека · Blood advances · 2023

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.

Rodríguez-Sevilla Juan Jose, Fernández-Rodríguez Concepción, Bento Leyre, Diez-Feijóo Ramón, Pinzón Sergio, Gibert Joan, Fernández-Ibarrondo Lierni, Lafuente Marta, Ferrer Ana, Sánchez-González Blanca, Gimeno Eva, Sainz Juan, Ramos Rafael, García Juan F, Colomo Lluis, Bellosillo Beatriz, Gutiérrez Antonio, Salar Antonio

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Several clinical risk models have been proposed to predict the outcome of follicular lymphoma (FL). The development of next-generation sequencing technologies has allowed the integration of somatic gene mutations into clinical scores to build genotyped-based risk models, such as the m7-Follicular Lymphoma International Prognostic Index (FLIPI). We explored 4 clinical or clinicogenetic-risk models in patients with symptomatic FL who received frontline immunochemotherapy. Of 191 patients with FL grades 1 to 3a, 109 were successfully genotyped. The treatment consisted of rituximab (R) plus cyclophosphamide, vincristine, and prednisone (R-CVP)/cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (72.5%) or R-bendamustine (R-B) (27.5%). The proportion of cases classified as high risk for FLIPI, FLIPI-2, PRIMA-prognostic index, or m7-FLIPI were 39.3%, 14%, 30.3%, and 22%, respectively. No case with low-intermediate FLIPI was upgraded in the m7-FLIPI, but 18 of the 42 high-risk patients with FLIPI were downgraded to low-risk m7-FLIPI. The sensitivity and specificity for the prediction of POD24 were highest for FLIPI. The discrimination between progression-free survival (PFS) and overall survival (OS) was the best for FLIPI (c-index: 0.644 and 0.727, respectively). When analyzed only in patients treated with R-B, m7-FLIPI showed a higher discrimination between PFS and OS. Thus, the FLIPI remains the clinical risk score with higher discrimination in patients with advanced FL treated with immunochemotherapy; however, the performance of the m7-FLIPI should be further investigated in patients treated with R-B.

Для цитирования: Rodríguez-Sevilla Juan Jose, Fernández-Rodríguez Concepción, Bento Leyre, Diez-Feijóo Ramón, Pinzón Sergio, Gibert Joan, Fernández-Ibarrondo Lierni, Lafuente Marta, Ferrer Ana, Sánchez-González Blanca, Gimeno Eva, Sainz Juan, Ramos Rafael, García Juan F, Colomo Lluis, Bellosillo Beatriz, Gutiérrez Antonio, Salar Antonio. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2022007949.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.